, Volume 14, Issue 4, pp 181–188 | Cite as

Metabolic effects of the association Berberis aristata/Silybum marianum: a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes

  • Giuseppina GuarinoEmail author
  • Teresa Della Corte
  • Morena Sofia
  • Lucia Carbone
  • Giampiero Marino
  • Emilia Martedì
  • Sandro Gentile


Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of its cholesterol-lowering, hypoglycemic, and insulinsensitizer effects. Because of its low oral bioavailability, it has been recently formulated along with silymarin (Silybum marianum) to improve intestinal absorption. The aim of our study was to evaluate, versus placebo treatment, the possible effect of its association with silymarin on abdominal fat in overweight/obese patients affected by type 2 diabetes mellitus. Using bioelectrical impedance at enrolment and after 6 months of treatment, we have evaluated the following clinical parameters: waist circumference, trunk fat, and visceral fat. Our results seem to indicate a clinically significant effect for the association berberine+silymarin.


berberine-silymarin abdominal fat type 2 diabetes mellitus obesity cholesterol 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62–66CrossRefGoogle Scholar
  2. 2.
    Catalàn V, Ambrosi JG, Rodrìguez A, Frühbeck G (2013) Adipose tissue immunity and cancer. Front Physiol 4:275CrossRefGoogle Scholar
  3. 3.
    Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493–499CrossRefGoogle Scholar
  4. 4.
    Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9CrossRefGoogle Scholar
  5. 5.
    Anand SS, Yusuf S (2011) Stemming the global tsunami of cardiovascular disease. Lancet 377:529–532CrossRefGoogle Scholar
  6. 6.
    Annali AMD 2012. www.aemmedi.itGoogle Scholar
  7. 7.
    Gentile S (2013) Lo studio START DIAB: descrizione del campione. Il Giornale AMD 16:129–137Google Scholar
  8. 8.
    [No authors listed] Berberine (2000) Altern Med Rev 5:175–177Google Scholar
  9. 9.
    Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G (2015) Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 61:69–81CrossRefGoogle Scholar
  10. 10.
    Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY (2007) Berberine induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 362:853–857CrossRefGoogle Scholar
  11. 11.
    Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256–2264CrossRefGoogle Scholar
  12. 12.
    Yao J, Kong W, Jiang J (2015) Learning from berberine: treating chronic diseases through multiple targets. Sci China Life Sci 58:854–859CrossRefGoogle Scholar
  13. 13.
    Vuddanda PR, Chakraborty S, Singh S (2010) Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 19:1297–1307CrossRefGoogle Scholar
  14. 14.
    Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X, Zhou L (2015) Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity. PLoS One 10:e0125667CrossRefGoogle Scholar
  15. 15.
    Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W, Ning G (2014) Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun 5:5493CrossRefGoogle Scholar
  16. 16.
    Choi JS, Kim JH, Ali MY, Min BS, Kim GD, Jung HA (2014) Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR- γ. Fitoterapia 98:199–208CrossRefGoogle Scholar
  17. 17.
    Han J, Lin H, Huang W (2011) Modulating gut microbiota as an anti-diabetic mechanism of berberine [Review]. Med Sci Monit 17:RA164–167CrossRefGoogle Scholar
  18. 18.
    Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, Li X, Ning G, Zhao L (2012) Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in highfat diet-fed rats. PLoS OneGoogle Scholar
  19. 19.
    Zhou J, Zhou S (2010) Berberine regulates peroxisome proliferator- activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol 649:390–397CrossRefGoogle Scholar
  20. 20.
    Hu Y, Fahmy H, Zjawiony JK, Davies GE (2010) Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 81:259–268CrossRefGoogle Scholar
  21. 21.
    Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296:e812–819CrossRefGoogle Scholar
  22. 22.
    Yu Y, Hao G, Zhang Q, Hua W, Wang M, Zhou W, Zong S, Huang M, Wen X (2015) Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol 97:173–177CrossRefGoogle Scholar
  23. 23.
    Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD, Xie L, Wang GJ (2010) Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 381:371–381CrossRefGoogle Scholar
  24. 24.
    Derosa G, Maffioli P, Cicero FG (2012) Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 12:1113–1124CrossRefGoogle Scholar
  25. 25.
    Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59:285–292CrossRefGoogle Scholar
  26. 26.
    Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717CrossRefGoogle Scholar
  27. 27.
    Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93:2559–2565CrossRefGoogle Scholar
  28. 28.
    Ni YX, Yang J, Fan S (1994) Clinical study on jiang tang san in treating non-insulin dependent diabetes mellitus patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 14:650–652Google Scholar
  29. 29.
    Dong H, Wang N, Zhao L, Lu F (2012) Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med 2012:591654CrossRefGoogle Scholar
  30. 30.
    Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y (2012) A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 166:99–105CrossRefGoogle Scholar
  31. 31.
    Tsai PL, Tsai TH (2004) Hepatobiliary excretion of berberine. Drug Metab Dispos 32:405–412CrossRefGoogle Scholar
  32. 32.
    Krishan S, Richardson DR, Sahni S (2015) Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol 87:365–377CrossRefGoogle Scholar
  33. 33.
    Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY (2002) The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 91:193–197CrossRefGoogle Scholar
  34. 34.
    Vitturi N, Soattin M, De Stefano F, Vianello D, Zambon A, Plebani M, Busetto L (2015) Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord 20:241–247CrossRefGoogle Scholar
  35. 35.
    Mateo Gallego R, Bea AM, Jarauta E, Perez-Ruiz MR, Civeira F (2012) Age and sex influence the relationship between waist circumference and abdominal fat distribution measured by bioelectrical impedance. Nutr Res 32:466–469CrossRefGoogle Scholar
  36. 36.
    Zamrazilovà H, Hlavaty P, Dusàtkovà L, Sedlàckovà B, Hainerovà IA, Kunesovà M, Skoch A, Hàjek M, Hainer V (2010) A new simple method for estimating trunk and visceral fat by bioelectrical impedance: comparison with mag- netic resonance imaging and dual X-ray absorptiometry in Czech adolescents. Cas Lek Cesk 149:417–422Google Scholar
  37. 37.
    Paquot N, Scheen AJ (2012) Which HbA1c and lipid targets in patients with type 2 diabetes? Rev Med Liege 67:98–103Google Scholar
  38. 38.
    Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G (2012) Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 5:213–217Google Scholar
  39. 39.
    Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G (2013) Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol 5:167–174Google Scholar
  40. 40.
    Di Pierro F, Bellone I, Rapacioli G, Puntignano P (2015) Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes 8:89–96CrossRefGoogle Scholar
  41. 41.
    Derosa G, Romano D, D’Angelo A, Maffioli P (2015) Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis 239:87–92CrossRefGoogle Scholar
  42. 42.
    Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD (2008) Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 57:1029–1037CrossRefGoogle Scholar
  43. 43.
    Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, Wang H (2008) Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol 35:303–309CrossRefGoogle Scholar
  44. 44.
    Derosa G, Limas CP, Macías PC, Estrella A, Maffioli P (2014) Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci 10:336–344CrossRefGoogle Scholar
  45. 45.
    Derosa G, Bonaventura A, Bianchi L, Romano D, D’Angelo A, Fogari E, Maffioli P (2013) Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 27:717–728Google Scholar

Copyright information

© CEC editore - Springer-Verlag Italia 2015

Authors and Affiliations

  • Giuseppina Guarino
    • 1
    Email author
  • Teresa Della Corte
    • 1
  • Morena Sofia
    • 1
  • Lucia Carbone
    • 1
  • Giampiero Marino
    • 1
  • Emilia Martedì
    • 2
  • Sandro Gentile
    • 1
  1. 1.Department of Experimental and Clinical MedicineSecond University of NaplesNaplesItaly
  2. 2.Diabetes Unit A.I.D. PorticiNaplesItaly

Personalised recommendations